Hypogonadism is a disturbance of HPTA homeostasis. Hypogonadism is inadequate gonadal function, as manifested by deficiencies in spermatogenesis and/or the secretion of testosterone. AAS, including testosterone, licit and illicit, administration induce a state of hypogonadism that continues after their cessation. This state is present during their administration but typically becomes symptomatic or manifest after AAS [...]

 
“The discovery of truth is prevented more effectively, not by the false appearance things present and which mislead into error, not directly by weakness of the reasoning powers, but by preconceived opinion, by prejudice.” Arthur Schopenhauer (1788–1860), German philosopher.
 
“All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it [...]

 
Historically, the difference in the beliefs held by the athletic and the medical communities on AAS are contradictory and irreconcilable. The development of AAS compounds originally were for treatment of hypogonadal dysfunction and commencement of delayed puberty in men and for growth promotion. AAS have, however, not always been used for pure medical purposes. Due [...]

From time to time, individuals write concerning questions on their medical care. In order to answer these inquiries, some of the case studies will be posted. These posts will include comments, suggestions, recommendations, etc. for medical care. Inquiries can be made either by posting a comment or email (mscally@asih.net). Anabolic steroid induced hypogonadism (ASIH) is [...]

 
HPT/Axis is developing enclomiphene, an isomeric form of clomiphene, for new clinical indications, in a long neglected disorder with no FDA approved treatment, potential to be first-in-class thus becoming the standard of care treatment, in a large market, and protected by method-of-use patents. For enclomiphene, the immediate business opportunity is the treatment of the adverse [...]